Tom Parker is a partner in the firm’s Intellectual Property Group. His practice focuses on patent litigation, prosecution, interferences, opinions and licensing, and he has represented and advised various businesses and academic institutions on matters in a host of areas, including pharmaceuticals, chemical compositions and biotechnology, as well as medical devices. He is registered to practice before the United States Patent and Trademark Office.
Mr. Parker has extensive expertise in matters involving the interaction among the patent and FDA laws in the drug-approval process relating to NDA, ANDA and § 505(b)(2) filings under the Hatch-Waxman Act, which includes developing patent strategies to assist clients in marketing drug products, litigating patents under the Hatch-Waxman Act and evaluating competitive patents.
Mr. Parker has more than four years of research experience, including work as a research scientist in microbiology and genetics. In particular, he worked as an associate scientist in the fields of human genetics and immunogenetics for Miles Pharmaceuticals, Inc. in West Haven, Connecticut.
- Counsel to large- and medium-sized pharmaceuticals companies in matters involving litigations under the Hatch-Waxman Act.
- Tried cases in the Southern and Northern Districts of New York and has substantively participated in or managed numerous litigations in many states.
- Frequently publishes and presents at seminars on various patent issues relating to the Hatch-Waxman Act and other patent-related matters.
-
A complete victory for our client, Merck & Cie! On January 31, 2013, the Hon. R.J. Sullivan of the Southern District of New York issued his decision regarding this matter that went to trial in 2011—and it was well worth the wait!
January 31, 2013
In the Press
-
Robert Hanlon, Thomas Parker, Natalie Clayton, Victoria Spataro and Lance Soderstrom, based in the firm’s New York office, received a favorable opinion on behalf of their client, Merck & Cie—a producer of pharmaceutical and dietary ingredients—in response to their action against Gnosis S.p.A. and Gnosis BioResearch S.A. for false advertising in connection with Gnosis’s manufacture and sale of a folate nutritional ingredient, which competes with Merck’s product, Metafolin®.
November 30, 2012
In the Press
-
Patent Licensing Transactions, Einhorn, 2002-present.
2007
-
"The Use of Patented Research Tools in Research and Development: Exempt from Infringement Under Safe Harbor Provision," Bioforum Europe, March 2007.
March 2007
-
"Generic Biologics: A Reality in the United States," Screening Trends on Drug Discovery, February 2007.
February 2007
-
“Authorized Generics Can Frustrate Patent Challengers by Generic Manufacturers,” Intellectual Property & Technology Law Journal, February 2005.
February 2005
-
“Federal Circuit to Decide Scope of Drug Patents During Term Extension Period,” IP Matters, October 2003.
October 2003
-
“Wide Scope – Federal Circuit to Decide Scope of Drug Patents During Term Extension Period,” Patentworld, September 2003.
September 2003
-
"Federal Circuit to Decide An Important Drug Issue: Do Extensions Cover Full Product or Just FDA-Approved Ingredients,” National Law Journal, September 2003.
September 2003
-
“Streamline Effect of New FDA Rules,” The Daily Deal, August 27, 2003.
August 2003
-
“Generics Battle Heats Up,” Pharmaceutical Executive, April 2003.
April 2003
-
“FDA Marketing Exclusivity for Single Enantiomers of Previously Approved Racemates,” Intellectual Property & Technology Law Journal, January 2003.
January 2003
-
“U.S. Pharma Companies Can Continue to Benefit from an Extended Pediatric Exclusivity Provision,” Pharmaceutical Executive, July 2002.
July 2002
-
“Best Pharmaceuticals for Children Act is Now Law,” National Law Journal, April 2002.
April 2002
-
“Pediatric Study Exclusivity – How Japanese Brand Name Drug Manufacturers Can Add Substantial Value to a Drug Product’s Life Cycle in the U.S.,” International Legal Strategy, April 2002.
April 2002
-
“Indemnification Provisions in U.S. Patent Licenses – A Guide for the Japanese Business,” International Legal Strategy, January 15, 2002.
January 2002